News >

Efficacy, Education, and Cost-Effectiveness Mark Latest Biosimilar Developments

Gina Columbus @ginacolumbusonc
Published: Friday, Aug 30, 2019

A cluster of clinical news in biosimilars has been announced over the last few days, with pooled data sets against reference products, an expected launch of a novel study, and a cost efficiency analysis. Beyond that, an expert in the field has shared his perspective on the challenges and ongoing need for education on biosimilars.

 

References

  1. Lee S, Lee H, Kim E. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-Hodgkin’s lymphoma: a systematic review and meta-analysis [published online August 22, 2019]. BioDrugs. doi: 10.1007/s40259-019-00376-z.
  2. McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma [published online August 21, 2019]. J Med Econ. doi: 10.1080/13696998.2019.1658591.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x